Searchable abstracts of presentations at key conferences in endocrinology

ea0090p390 | Endocrine-related Cancer | ECE2023

Efficacity of combination of Lenvatinib and PPRT in severe hypersecretion of VIP

Raluca Mitru Natalia , Hadoux Julien , Lamartina Livia , Pani Fabiana , Baudin Eric , Moog Sophie

Introduction: VIPomas are rare neuroendocrine tumors (NET), usually located in the pancreas that secrete vasoactive intestinal polypeptide (VIP) leading to high-volume watery diarrhea and complications such as hypokalemia, acidosis and dehydration. The management of VIPoma symptoms is often challenging when surgical resection of all the lesions is not feasible. Treatments are then based on somatostatin analogs (SSA) and may also include hepatic chemoembolization, systemic chem...

ea0049ep179 | Endocrine tumours and neoplasia | ECE2017

Serum succinate: investigation of its putative role as a new biomarker in malignant SDH-x mutated pheochromocytoma-paraganglioma patients?

Lamy Constance , Hadoux Julien , Mercier Lionel , Bailleux Dorian , Hescot Segolene , Paci Angelo , Baudin Eric , Broutin Sophie

Introduction: Malignant paraganglioma/pheochromocytoma (MPP) are very rare neuroendocrine tumors with heterogeneous prognostic and no gold-standard treatment. MPP can be associated with germline mutations at SDH-x genes which encode for the succinate dehydrogenase that catalyzes the oxidation of succinate to fumarate. SDH-x mutations lead to inactivation of the enzyme and thus accumulation of succinate.Aim: This project aims to evaluate...

ea0022oc4.4 | Adrenals | ECE2010

Combined anticortisolic therapy by metyrapone, ketoconazole and mitotane: an alternative to adrenalectomy in severe Cushing’s syndrome

Kamenicky Peter , Droumaguet Celine , Baudin Eric , Salenave Sylvie , Trabado Severine , Cazabat Laure , Chanson Philippe , Young Jacques

Context: Mitotane due to its adrenolytic action is highly effective in long-term management of ACTH-dependent Cushing’s syndrome (CS). However, the slow onset of its anticortisolic effect makes its use problematic in severe CS, when very rapid therapeutic response is required. Association with metyrapone and ketoconazole, rapidly acting steroidogenesis inhibitors, could warrant CS control while waiting for the full efficiency of mitotane and thus avoid urgently performed ...

ea0032p516 | Endocrine tumours and neoplasia | ECE2013

Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma

Kerkhofs Thomas , Baudin Eric , Terzolo Massimo , Allolio Bruno , Chadarevian Rita , Leboulleux Sophie , Mantero Franco , Haak Harm , Fassnacht Martin

Introduction: Current medical treatment of adrenocortical carcinoma (ACC) is based on mitotane alone or in combination with cytotoxic chemotherapy. However, very little is known about the pharmacokinetic properties of mitotane and dosing schedules are based on clinical experience only. The aim of this study was to investigate the relationship between mitotane dose and plasma concentration comparing two pre-defined treatment regimens. Secondary objectives were to evaluate safet...

ea0026oc2.1 | Neuroendocrinology | ECE2011

Etoposide, doxorubicin, cisplatin, and mitotane versus streptozotocin and mitotane in adrenocortical carcinoma: preliminary results from the first international phase III trial: the FIRM-ACT study

Fassnacht Martin , Terzolo Massimo , Allolio Bruno , Baudin Eric , Haak Harm , Berruti Alfredo , Mueller Hans-Helge , Skogseid Britt

Background: No randomized trials have been conducted in adrenocortical carcinoma (ACC) patients. Treatment recommendations for this rare but aggressive disease have been based on data from small phase II trials. We have now performed the first randomized phase III trial, comparing etoposide, doxorubicin, cisplatin, plus mitotane (EDP-M) against streptozotocin plus mitotane (Sz-M).Methods: Three-hundred and four chemotherapy-naive patients with ACC not am...

ea0022p418 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?

Leboulleux Sophie , Deandreis Desiree , Ghuzlan Abir Al , Auperin Anne , Dromain Clarisse , Young Jacques , Schlumberger Martin , Baudin Eric

Context: Peritoneal carcinomatosis (PC) is a rare site of distant metastasis in patients with adrenocortical cancer (ACC). One preliminary study suggests an increase risk of PC after adrenalectomy through laparoscopic approach of ACC.Objective: The objective of the study was to search for risk factors of PC including surgical approach. This was a retrospective cohort study conducted in an institutional practice.Patients: Sixty-four...

ea0089c1 | Clinical – Chemo/SSA/Biologics | NANETS2022

Progression-Free Survival in Patients with Bronchopulmonary Neuroendocrine Tumors Treated with Lanreotide or Placebo: Adjustment for Crossover Effects in Placebo Arm

Singh Simron , Buikhuisen Wieneke , Capdevila Jaume , Caplin Martyn E , Grohe Christian , Horsch Dieter , Raderer Markus , Reidy-Lagunes Diane , Wolin Edward M , Pommie Christelle , Mai Truong Xuan , Baudin Eric

Background: SPINET was a phase 3 trial (NCT02683941) in patients with well-differentiated, advanced bronchopulmonary neuroendocrine tumors (NETs; typical and atypical carcinoids [TCs and ACs]). During the double-blind (DB) period, patients were randomized (2:1) to receive lanreotide autogel/depot (LAN; 120 mg) or placebo (PBO) every 28 days; in the optional open-label (OL) phase, all patients received LAN. Recruitment was stopped early due to slow accrual; all eligible patient...

ea0063p826 | Adrenal and Neuroendocrine Tumours 3 | ECE2019

The French COMETE-Cancer network for adrenal cancer: 10 years of activity as part of a national plan for clinical care of rare cancers

Libe Rossella , Tabarin Antoine , Chabre Olivier , Laboureau Sandrine , Goichot Bernard , Vezzosi Delphine , Lefebvre Herve , Verges Bruno , Niccoli Patricia , Vanthyghem Marie-Christine , Baudin Eric , Bertherat Jerome

Introduction: The French National Institute of Cancer (INCa) launched supported by the Ministry of Health in 2008 a program for the recognition of national networks for the management of rare cancers. Among the 23 selected networks COMETE-Cancer was recognized by INCa in 2009 for Adrenocortical carcinoma (ACC) and malignant pheochromocytoma/paraganglioma (MPP). At that time 60–120 new ACC/year and 30 new MPP/year were expected at the national level....

ea0032p544 | Endocrine tumours and neoplasia | ECE2013

Multimodal combination of interferon and loco-regional treatment for disease control in progressive metastatic pheochromocytoma/paraganglioma patients

Hadoux Julien , Deandreis Desiree , Caramella Caroline , Leboulleux Sophie , Al Ghuzlan Abir , Chougnet Cecile , Dumont Frederic , Deschamps Frederic , Schlumberger Martin , Baudin Eric

Interferon-α (IFN-α) has shown some activity in neuroendocrine tumors with disease stabilizations. Malignant pheochromocytoma and paraganglioma (MPPGLs) have a heterogeneous behavior with a slow progression rate, most of the time and a high frequency of bone metastases. Stabilizing disease and preventing skeletal-related events are two goals to achieve in the management of MPPGLs patients.This retrospective study evaluated a multimodal strategy...

ea0026p27 | Adrenal cortex | ECE2011

Do mitotane levels impact on the outcome of patients treated adjuvantly following radical resection of adrenocortical cancer (ACC)?

Ardito A , Al Ghuzian A , Fassnacht M , Daffara F , Leboulleux S , Wortmann S , Zaggia B , De Francia S , Volante Marco , Gonzaga Luigi , Berruti Alfredo , Allolio Bruno , Baudin Eric , Terzolo Massimo

We have demonstrated that adjuvant mitotane prolong recurrence free survival (RFS) in patients with radically resected ACC. Aim of the present study was to correlate mitotane levels with patient outcome in an adjuvant setting in 3 different referral centres in Europe. There were 120 patients (45 W, 75 M, median age 44 years, range 16–76) radically resected for ACC who were treated adjuvantly with mitotane from 1996 to 2010. ACC was stage I in 10 cases, II in 73, III in 31...